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Purpose: To investigate the immunohistochemical expression (IGF-1,
EGFr, EGF, c-erbB-2/HER-2/neu, PDGF-A, PDGF-B, FGF and VEGF) in
patients with Graves’ ophthalmopathy. Methods: Twenty-four samples
(Graves’ ophthalmopathy patients) underwent lateral rectus muscle and
surrounding fibrous and adipose tissue biopsy. The control group was
obtained by strabismus surgery. Correlation between clinical- ophthalmo-
logic, endocrinological, ultrasonographic findings, and immunohistoche-
mical expression was performed. Results: IGF-1: There were 7 positive
cases (29.2%). There was a direct relation with higher CAS (clinical activity
score) in all of them and if only CAS equal or higher than 5 was considered,
this was 54.5%. FGF: There was expression in 5 cases (20.8%) with a direct
relation in all those with higher CAS (>5) (45.4%). VEGF: There were two
positive cases (8.3%) for VEGF in endothelial cells, in these cases the
patients also presented CAS higher than 5. There was no expressions of
all growth factors in the control group. Conclusions: All patients, except
one, with positive expression of FGF, IGF-1 and VEGF showed CAS
greater than 5, suggesting in this way an important role of these growth
factors in the pathogenesis and severity of Graves’ ophthalmopathy. Ho-
wever, statistical analysis revealed only significant association between
IGF-1 and male sex (P=0.034). Low ultrasound reflectivity and endocrine
status may not correlate directly with disease activity or with immuno-
expression of growth factors and c-erbB-2/HER-2/neu.
ABSTRACT
INTRODUCTION
Thyroid associated ophthalmopathy (TAO) is a potentially severe disease.
Ophthalmopathy, the most frequent extra-thyroidal manifestation of
Graves’ disease, results from an increased volume of the orbital tissues(1).
Orbital T cells, fibroblasts, adipocytes and perhaps other residential cells
would release numerous cytokines, growth factors and inflammatory me-
diators, many of which act as potent stimulators of glycosaminoglycan
accumulation and edema formation(2).
The pituitary gland is rich in FGF(3) and IGF-1(4), and these growth
factors are well known to stimulate fibroblast proliferation and secretion of
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collagen and glycosaminoglicans. It is interesting that pa-
tients with ophthalmopathy present in their extraocular mus-
cles more IGF-1 receptors(5).
We attempted to investigate the immunohistochemical ex-
pression of c-erbB-2/HER-2-neu, IGF-1 (Insulin-like Growth
factor-1), EGFr (Epidermal Growth Factor receptor), EGF (Epi-
dermal Growth Factor), PDGF-A (Platelet-derived Growth Fac-
tor-A), PDGF-B (Platelet-derived Growth Factor-B), FGF (Fi-
broblast Growth Factor) and VEGF (Vascular Endothelial Grow-
th Factor) in retroocular connective tissue and extraocular
muscles in patients with Graves’ ophthalmopathy and their cli-
nical correlation.
METHODS
This was a study of twenty-two sequential patients with
Graves’ ophthalmopathy, who were referred to the Federal Uni-
versity of São Paulo, São Paulo, Brazil.
Two ophthalmologists evaluated all patients. The clinical
activity score (CAS) was used(6). To assess the disease seve-
rity, the NOSPECS classification(7) was used.
The diagnosis of Graves’ ophthalmopathy was based on
the presence of the typical clinical and laboratorial features in
combination with enlargement of extraocular eye muscles on
ultrasound scan as published by Bartley & Gorman(8).
Eye muscle diameter and reflectivity was assessed with stan-
dardized A- and B-mode ultrasonography of both orbits, using
an Ophthscan-S unit (ALCON) with 10 MHz frequency (9). In the
A- and B-mode, the sound beam was directed perpendicularly
to the axis of the rectus bulbi muscle based on Polaroid pic-
tures taken during the examination. The eye muscle reflecti-
vity was defined as the mean of the distance from the baseline
to the top of all spikes within the anterior and posterior muscle
sheaths in relation to the sclera spike, which was assumed to be
100%. These results were expressed as high, medium or low
reflectivity, using the standard methods described by Prum-
mel et al.(10).
There were 20 patients who had one biopsy, and 2 patients
who had both eyes biopsied. In general our choice was based
in the worse eye, if there was disease activity. Samples of con-
nective tissue surrounding muscle fibres and lateral rectus
muscle from all patients were obtained by the same ophthal-
mologist, with the patient’s informed consent and Institutio-
nal Review Board (IRB)/Ethics Committee approval. All biop-
sies, which measured between 2.2-3.8 mm, were performed
using the transconjunctival approach, with tissue taken from
the superior portion of lateral rectus muscle and including
surrounding tissues. The samples from the control group (n=4)
were obtained during routine non-thyroid-related corrective
strabismus surgery. Half of the obtained tissue was frozen
immediately after surgery at -70° C. The other half was kept for
12-24 hours in 10% buffered formalin, 5 minutes under pressu-
re in a pressure cooker and processed for routine histological
sections(1).
For the routine stains, such as hematoxylin and eosin, pe-
riodic acid Schiff (PAS), alcian blue, and for the immuno-
histochemical study, paraffin 4-μm thick sections were cut.
For immunohistochemistry, the sections were deparaffinized




 solution for 30 min.
Sections were then incubated for 20 min with the following
antibodies: c-erbB-2/HER-2/neu: Polyclonal antibody for
rabbit IgG, (1:50 dilution). EGFr: Polyclonal antibody for rabbit
IgG, (1:50 dilution). EGF: Polyclonal antibody for rabbit IgG
(undiluted). IGF-1: Polyclonal antibody for goat IgG (undilu-
ted). FGF: Polyclonal antibody for rabbit IgG (1:50 dilution).
PDGF A e B: Polyclonal antibody for rabbit IgG (1:50 dilution).
VEGF: Polyclonal antibody for rabbit IgG (1:50 dilution), all
from Santa Cruz Biotechnology Inc., USA.
For detection the streptavidin-biotin complex- Duet mou-
se/rabbit, Dako Corporation, Santa Barbara, California (K0492/
lot 126), in a dilution of 1:800 was used.
After washings with 0.01 mM, pH 7.4 phosphate-buffered
saline (PBS), sections were counterstained with hematoxylin,
dehydrated and mounted.
We assessed associations between variables using Spear-
man’s rank correlation coefficient for continuous variables
and Fisher’s exact test for categorical variables.
RESULTS
The study group consisted of 22 patients, with 24 biopsy
specimens, which fulfilled the inclusion criteria. As a com-
plication of the biopsy only two patients presented mild pain
after the procedure, which disappeared in two days with oral
NSAID. The control group consisted of 3 patients, with 4 biop-
sies (one of whom was subjected twice to strabismus surgery).
There were 10 males and 12 females in Graves’ group and 3
females in a control group. The age range was 21 to 58 years, the
average being 41 years. In terms of drug usage, 8 patients were
on thiamazol, 5 were taking propranolol, 3 patients predniso-
lone, 2 L-tiroxin sodium salt, 2 colchicine, 1 diclofenac sodium,
and 1 was on propylthiouracyl. Time of biopsy from onset of
ocular disease ranged from 1 month to 84 months, with an ave-
rage of 20.6 months. With regard to the endocrinological status,
16 patients were euthyroid, 7 patients presented with hyper-
thyroidism, and 1 patient presented with hypothyroidism.
The echography results disclosed an enlargement in all
extraocular recti muscles except one, following the patterns
found by Byrne et al.(11).
Our immunohistochemistry findings for c-erbB-2 (HER2-
neu), EGFr, EGF, IGF-1, FGF, PDGF-A, PDGF-B and VEGF were:
C-erb-2- immune reaction was considered non-specific in the
cytoplasm of neutrophils, and around vessels in 4 cases (16.7%),
and negative in all the rest. If we considered only CAS equal or
higher than 5 then 27.3% were non-specific. There were no specific
immune stains for fibrous tissue, fibroblasts or muscle tissue.
EGF-r (Epidermal Growth Factor-receptor): There was no
immunoreactivity in all biopsied samples.
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EGF (Epidermal Growth Factor): There was immunoreac-
tivity in two cases (8.3%), non-specific in neutrophils. There
was no reaction in muscular fibrous tissue.
IGF-1 (Insulin-like Growth Factor-1): Seven cases were po-
sitive (29.2%). The immunoreactivity was mainly in the con-
nective tissue and fibroblasts (Figure 1A). We could not de-
monstrate this reaction in muscle fibres and fat tissue (in these
tissues, the reaction was mild and considered non-specific).
In the 7 cases of positive IGF-1, there was a correlation
with greater CAS (at least 5) in the cases 3a, 3b (Figure 1A),
6,7,12 and 21, (54.5%) with exception of case 13. Nevertheless,
there was a patient with CAS 10 and negative IGF-1.
FGF (Fibroblast Growth Factor): There was positive expres-
sion in 5 cases (patients 3a and 3b, 6, 12 and 22) (20.8%) in 24,
and there was a direct relation between positivity and higher
CAS in all of these. If we considered only patients with CAS
equal or higher than 5, then 45.4% were positive. The immu-
noreactivity was located in the cytoplasm of fibroblasts and
connective tissue (Figures 1A, B and C).
PDGF-A and PDGF-B (Platelet Derivate Growth Fac-
tor): There was no expression of alpha and beta-PDGF. In two
cases (16 and 20), there was a non-specific stain in amorphous
tissue.
VEGF (Vascular Endothelial Growth Factor): There were two
cases (7 and 12) (8.3%) with immunoreactions for VEGF in
endothelial cells; in these cases the patients also presented
CAS higher than 5 (Figure 1D). All these data are summarized in
table 1, and the relevant numbers of samples and IGF-1, FGF and
VEGF expression in table 2.
In the control group, which consisted of 4 samples, there
was no expression of any growth factor and c-erbB-2.
Our statistical analysis revealed evidence of as associa-
tion between IGF-1 and sex (P=0.034, Fisher’s exact test) (Gra-
ph 1). We found no evidence of any association between the
other variables under study, however it is important to realize
that the number of patients in the study is small and thus the
power to detect significant differences is low.
DISCUSSION
There may be less difference between the six extraocular
muscles in their pathological involvement than is clinically
Figure 1 - (A) IGF-1 positive immunoexpression in connective tissue. Muscle fibers IGF-1 immunoexpression negative. (40X). (B) Connective tissue.
FGF immunostaining severe immunoreaction at cytoplasmic level in fibroblasts and diffusely in connective tissue. (400X). (C) Connective tissue.
FGF immunoexpression in fibroblasts, cytoplasmic level, granular shape. (1000X). (D) VEGF immunostainning. VEGF immunoexpression in
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Table 1. Clinical, endocrinological, radiological and immunohistochemistry data of patients with Graves’ ophthalmopathy
Patient Sex Age Medication radiotherapy CAS Endocrinology Ultrasound Immunohistochemistry
01 M 41 T 5 mg 6 E R=4.5 Me c-erbB-2 + Neutrophils
02 F 58 T 30 mg 1 He R=8.4 Me Negative
03 a M 33 Pr 10 mg 7 He R= 4.3 Me IGF-1 + FGF + Fibroblasts
C 1 mg, T 15 mg
03 b M 33 T 5 mg 7 Ho L=5.7 H c-erbB-2 + Neutrophils IGF-1 + FGF + Fibroblasts
04 a M 53 N 10 He D=11.0 Me/L c-erbB-2 + Neutrophils EGF + Neutrophils
04 b M 53 Pr 40 mg 10 E L=11.1 Me/L Negative
05 F 28 N 2 E L=5.8 M Negative
06 M 21 Pl 40 mg, T 5 mg 5 E R= 6.2 Me IGF-1 + FGF + Fibroblasts
07 M 42 D 50 mg 7 E R=5.1 Me IGF-1 + VEGF + Vessels
08 F 42 N 1 E R=6.6 Me/L Negative
09 M 27 N 1 E R=5.5 Me/L Negative
10 F 32 N 2 E L=5.7 Me Negative
11 F 28 Pl 40 mg, T 10 mg 2 He L=5.6 Me/H c-erbB-2 + Neutrophils EGF + Neutrophils
12 F 32 T 5 mg 5 He R=5.0 Me IGF-1 + FGF + Fibroblasts VEGF + Vessels
13 M 33 LTS 150 μg 2 E L=5.3 Me IGF-1 +
14 F 26 LTS 100 μg
(send to radiotherapy) 6 E R= 6.8 H Negative
15 F 35 N 3 He R=7.5 L Negative
16 F 35 N 3 E R=6.4 L PDGF-A + Amorphous substance
17 F 30 Pr 40 mg 1 E R=4.4 Me/H Negative
18 M 23 T 40 mg
Post radiotherapy 3 E R=3.3 H Negative
19 F 40 T 10 mg, Pl 40 mg 1 He L=6.8 Me Negative
20 F 48 N 1 E R=4.1 Me PDGF-A + Amorphous substance
21 M 45 C 1 mg 6 E L=5.4 Me IGF-1 +
22 M 34 Pt 60 mg, Pl 80 mg 6 E L=5.5 Me FGF + Fibroblasts
M= male; F= female; N= negative; P= positive; R= right; L= left; Me= medium; L= low; H= high; E= euthyroidism; He= hyperthyroidism; Ho= hypothyroidism; T= thiamazol;
Pr= prednisone; C= colchicine; D= diclofenac sodium; LTS= L-thyroxin sodic; Pl= propranolol; Pt= propylthiouracyl
Table 2. Number of samples and IGF-1, FGF and VEGF expression
IGF-1 FGF  VEGF
Positive 7 5 2
Negative 17 19 22
Total 24 24 24
apparent(12). Related to distribution of affected eye muscles,
there are many controversies.
There was a paper showing that the muscles were not
equally involved (e.g. the medial and the inferior being more
frequently enlarged than the superior and lateral recti(13). Con-
versely, no difference was found on A-scan (e.g., the medial,
lateral, and superior recti all had an abnormal reflectivity in
approximately 50% of patients(10). In addition, the muscles
appearing normal on CT scan had an abnormal reflectivity in
the A-mode. These findings are in agreement with a previous
report(9) and suggest that there is an even distribution of in-
volvement among all the muscles, in accordance with an other
report(14). This is a critical point if any conclusion of our paper,
i.e., the muscle on which we performed the biopsy was not
necessarily involved in an inflammatory process at that time,
even if an ultrasound reflectivity was abnormal. As there appears
to be no difference between inflammatory patterns in any of
the extraocular muscles, we chose for this reason to perform a
biopsy of the lateral recti muscle because of easier surgical
exposure.
The patients in our study had a variety of stages of CAS
scores (Table 1) when the biopsy was performed, but the
patients also presented different stages of their disease,
and some patients may had more disease activity earlier. Five
patients had ongoing steroid medication, and three had radio-
therapy, which may have diminished the inflammatory res-
ponse. Furthermore, the inflammatory process may be locali-
zed and not equally distributed throughout the muscle(14).
Thus, the biopsies might not be representative for the whole
muscle.
A smaller percentage of patients with Graves’s disease
had both Graves’s ophthalmopathy and pretibial dermopathy.
We found only 2 patients with pretibial dermopathy, and both
showed IGF-1 and FGF and CAS greater than 5. Patients dis-
playing one or more of these extrathyroidal manifestations
frequently develop severe Graves’ ophthalmopathy(15). It is
possible that an expression of IGF-1 and FGF predispose to a
worse outcome of Graves’ ophthalmopathy.
A great variety of tissues are capable of producing their
own IGF-1, suggesting in this way, that IGF-1 might be able to
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act at the autocrine and paracrine level. High circulating levels
of this hormone indicate some endocrine role(16).
There is a paper(17) that demonstrated that IgG prepared
from patients with Graves’ disease with or without overt oph-
thalmopathy interact with IGF-1 binding sites on orbital fibro-
blasts.
There was an(18) analysis of glycosaminoglycans synthe-
sized by retroocular fibroblasts in culture derived from an
individual not suffering from thyroid disease and from three
patients with Graves’ ophthalmopathy. The effects of IGF-1
and PDGF on hyaluronan and proteoglycan synthesis were
studied separately and in combination. In our study we found
IGF-1 expression in seven cases, and in two cases, PDGF-A in
a very non-specific presentation in amorphous material. Our
results might imply a more relevant role for IGF-1 when com-
pared with PDGF.
 It was(5) found that IGF-I may be a determinant of thyroid
cell growth, both normal and in certain thyroid diseases inclu-
ding Graves’ disease, and may be important in abnormal sti-
mulation of retroocular connective tissue in Graves’ as well.
FGF induces a proliferative response in mesodermal and
neuroectodermal cells. This induction may create angiogene-
sis, healing and neural regeneration in vivo. Of these, one of
the most important, angiogenesis, is directly related to the inten-
sity and speed of recovery(19).
There were studies on the role of FGF in the pathogenesis of
nodular goiter. Thyroid epithelial cells are known to produce
several growth factors and cytokines, which influence thyroid
cell growth and function in an autocrine and/or paracrine man-
ner(20). It is already known that IGF-1 is overexpressed in toxic
adenomas whereas EGF is found predominantly in thyroid neo-
plasia. Most bFGF immunostaining was found in the connec-
tive tissue of all thyroid tissues with predominance in adeno-
mas and Graves’ diseases. In our study we found a positive
expression of IGF-1 in 7 cases, more related with non-neoplastic
growth, i.e. Graves’ ophthalmopathy, and no expression of EGF,
which seems related more with tumor processes.
Conversely, it was found that bFGF is synthesized in the
neoplastic follicular cells of the thyroid, and aFGF and bFGF
may have important roles in the neoplastic proliferation of
follicular cells(21).
There were other authors who found that TSH stimulates
an increase in thyroid EGF receptors by increasing intra-
cellular cAMP(22).
VEGF can induce angiogenesis in a complex way, which
involves selective division of endothelial cells, vascular mem-
brane degradation surrounded by cellular matrix and migration
of endothelial cells(23).
Basically, VEGF increases vascular permeability and this
became evident minutes after injection(24-25).
This could be a reason that our patient number seven, who
was being treated with diclofenac sodium, in spite of this still
expressed VEGF, and still had CAS 7.
 A significant increase in serum VEGF levels was reported in
patients with untreated Graves’ disease and goiter Hashimoto’s
thyroiditis compared with those in healthy subjects(26). Serum
VEGF levels in untreated patients with subacute thyroiditis were
significantly higher than those in patients with untreated Graves’
disease or Hashimoto’s thyroiditis. In our study, one of these
patients presented with a hyperthyroidism when biopsied, and
the other with euthyroidism and VEGF was expressed in both
biopsies. Clinically both had scores higher than CAS 5.
Graph 1 - Comparison between IGF-1 expression in male and female patients
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Graph 2 - Number of samples and IGF-1, FGF and VEGF expression in
patients with CAS <5 and CAS= >5
There were suggestions that Placenta Growth Factor
(PlGF) and vascular endothelial growth factor (VEGF), relea-
sed by thyrocytes in response to the chronic activation of the
TSH receptor pathway, may act through a paracrine mecha-
nism on thyroid endothelium(27).
The higher levels of VEGF expression in differentiated
thyroid cancers of follicular cell origin were reported sugges-
ting a role in oncogenesis(28).
However, VEGF is also expressed in normal tissues such as
kidney, lungs, heart which do not show evidence of angioge-
nesis(29-30).
Another important stimulus for VEGF expression is a limi-
tation in oxygen supply. Lower cellular pH and a higher con-
centration of lactate could induce the release of angiogenic
peptides from macrophages and tumor cells(23). It is well known
that in Graves’ ophthalmopathy, the restricted orbital com-
partment is associated with compression of orbital tissue and
slow venous return. This may result in a limitation in the oxygen
supply, lower pH, and a higher concentration of lactate which
could stimulate the VEGF expression, independent of other
mechanisms such as inflammation.
CONCLUSION
In our study, all patients, but one, with positive expression
of FGF, IGF-1 and VEGF, showed CAS greater than 5 (Graph 2).
This suggests an important role of these growth factors in the
pathogenesis and severity of Graves’ opthalmopathy. As in
previous reports, we found an inflammatory process in con-
nective tissue and not in muscle fibres. The immunoexpres-
sion was found in neutrophils and amorphous substance in
non-specific reactions. Fibroblasts and endothelial cells had a
strong immunoexpression of IGF-1. Fibroblasts had a strong
immunoexpression of FGF, and endothelial cells had a strong
immunoexpression of VEGF.
Neither low or low/medium ultrasound reflectivity showed
IGF-1, FGF and VEGF expression.
The endocrine status may not correlate directly with disea-
se activity or even with immunoexpression of growth factors.
A better understanding of the pathogenesis of Graves’
disease may allow the development of new preventive and
therapeutic strategies to ameliorate the quality of life of Gra-
ves’ disease patients.
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RESUMO
Objetivo: Investigar a expressão imuno-histoquímica de IGF-1,
EGFr, EGF, c-erbB-2/HER-2/neu, PDGF-A, PDGF-B, FGF e
VEGF na oftalmopatia de Graves. Métodos: Vinte e dois pa-
cientes (oftalmopatia de Graves) foram submetidos à biópsia
do músculo reto lateral e tecido fibroso e adiposo adjacente. O
grupo controle foi de pacientes de cirurgia de estrabismo. Foi
feita correlação entre achados clínico-oftalmológicos, endo-
crinológicos, ultra-sonográficos e da expressão imuno-histo-
química dos fatores de crescimento. Resultados: IGF-1: Houve
7 casos positivos (29,2%). Houve correlação direta com o CAS
(clinical activity score) elevado em todos os casos e em que
consideramos CAS apenas acima de 5, em 54,5%. FGF: Houve
expressão em 5 casos (20,8%) com relação direta com CAS
elevado em todos os casos e em que consideramos CAS maior
que 5 (45,4%). VEGF: Houve dois casos positivos (8,3%) para
VEGF nas células endoteliais e estes casos também apresenta-
vam CAS maior que 5. A imunorreatividade foi negativa em
todo grupo controle. Conclusão: Todos os pacientes, com
exceção de um, com expressão positiva para FGF, IGF-1 e
VEGF mostraram CAS maior que 5, sugerindo importante papel
destes fatores de crescimento na patogênese e gravidade da
oftalmopatia de Graves. Entretanto, a análise estatística de-
monstrou associação significativa entre IGF-1 e o sexo mascu-
lino (P=0,034). Baixa refletividade ao ultra-som e condição
endócrina não estiveram correlacionadas.
Descritores: Imuno-histoquímica; Receptor erbB-2/análise;
Fator de crescimento insulin-like I/análise; Receptor do fator
de crescimento epidérmico/análise; Fator de crescimento epi-
dérmico/análise; Receptor tipo alfa para fator de crescimento
derivado de plaqueta/análise; Proteínas proto-oncogênicas
c-sis/análise; Fatores de crescimento de fibroblastos/análise;
Fator A de crescimento do endotélio vascular/análise; Oftalmo-
patia de Graves/metabolism
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